Central and East European Oncology Group

  • Members
    Members

    CEEOG has greatly expanded and now includes 35 academic andcommunity hospitals from Poland, Romania, Slovakia, Bulgaria, Slovenia, Croatia, Bosnia and Hercegovina, Yugoslavia, Hungary, Czech Republic and Russia.

     

     

     

Polish Brain Metastasis Consortium

pbmc-logo

The group was founded in 2005 by Dr. Renata Duchnowska from the Military Medical Institute in Warsaw as a result of establishing an informal network of some Polish oncology centers. A year later group teamed up with foreign research groups and academic centers. In 2008, the patronage of the Group's research covered the CEEOG.

Conference abstracts

  • S. Kerpel-Fronius, Z. Mechl, J. Csetenyi, T. Nagykalnai, F. Gyergyay, J. Jassem et al.: Pharmacocinetic and response rate of 5-Fluorouracil given in daily 4h infusion combined with cisplatin in head and neck cancer. Phase I-II study. Proc. Annual ASCO meeting, 1988, 150.

  • K. Kolaric, S. Eckhardt, J. Jassem, E. Kanitz, A. Tamas, C. Intini, Z. Schoket, M. Pawlicki. Phase II randomized study of high-dose epirubicin combined with either cyclophosphamide or cisplatin in small cell lung cancer. Proc 16 Int Congress of Chemother, Jerusalem 1989, 877.1-877.2.

  • E. Kanitz, S. Eckhardt, K. Kolaric, J. Jassem: High-dose epi-doxorubicin combination treatment in untreated extensive small cell lung patients. Eur Respir Journal 1989, 2 (suppl. 8), 1989.

  • K. Kolaric, S. Eckhardt, C. Intini, Z. Mechl, J. Jassem: The antitumor activity of high-dose epirubicin in small cell lung cancer Abst. 9th Asia Pacific Cancer Conference 1989, Lahore, str. 6

  • J. Jassem, E. Hall, R. Commbes, J. Bliss, L. Gibson:  Surgical approaches to early breast cancer in the Intergroup Exemestane Study: large differences by country and geographical region. Eur J Cancer, 2004, 2, 162

  • R. C. Coombes, R. Paridaens, J. Jassem, C. J. Van de Velde, T. Deolzier, S. E. Jones, E. Hall, L. S. Kilburn, C. F. Snowdon, J. M. Bliss. : First mature survival analysis of the Intergroup Exemestane Study: A randomized trial in disease-free, postmenopausal patients with early breast cancer randomized to continous tamoxifen or switch to exemestane followin an initial 2-3 years of adjuvant tamoxifen. J Clin Oncol, 2006, 24, Suppl. 1, 9s

  • J. Jassem, R.C. Coombes, B. Ireland, E. Hall, C.F. Snowdon, J.M. Bliss : Approaches to postmastectomy radiotherapy (PMRT) in the intergroup exemestane study (IES). Radioth Oncol 2006, 81, Suppl 1, S278

  • G. Bertelli, E. Hall. E. Ireland, J. Jassem, J.M. Bliss, C.F. Snowdon, R.C. : Coombes.Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment. Breast Cancer Res Treat, 2007, 106, suppl. 1, S111

  • Duchnowska R, Jassem J, Thorat M, Morimiya A, Li L, Sledge GW Jr, Biernat W, Szczylik C, Steeg P, Badve S. : Gene expression analysis for prediction of early brain metastasis in HER2-positive breast cancer patients.  J Clin Oncol 2008; 26 (supl): 45s.

  • Duchnowska R, Jassem J, Shen C, Thorat M, Li L, Morimiya A, Zhao Q, Biernat W, Mandat T, Staszkiewicz R, Och W, Szostak W, Gugala K, Trojanowski T, Czartoryska-Arlukowicz B, Szczylik C, Nakshatri H, Steeg P, Sledge G, Badve S : Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC). Abst 31st Annual San Antonio Breast Symposium 2008; 164s (abst. 2028).

  • Duchnowska R, Jassem J, Shen C, Thorat M, Li L, Morimiya A, Zhao Q, Biernat W, Mandat T, Staszkiewicz R, Och W, Szostak W, Gugała K,Trojanowski T, Czartoryska-Arlukowicz B, Szczylik C, Nakshatri H, Steeg P, Sledge GW, Badve S : Molecular features of matched brain metastasis (BM) versus the primary breast cancer (PBC). Abst Book 6th, Opatia, 2009; 93. Central European Oncology Conference

  • J.M. Bliss, L.S. Kilburn, R.E. Coleman, J.F. Forbes, A.S. Coates, S.E. Jones, J. Jassem, T. Delozier, J. Andersen, R.J. Paridaens, R.C. Coombes, on behalf off the IES Steering Committee. Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES). Cancer Res 2009; 69: 487s

  • Duchnowska R, Szostakiewicz B, Jankowski T, Arlukowicz-Czartoryska B, Wysocki PJ, Huang W, Bates MP, Weidler J, Haddad M, Jassem J : Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy. J Clin Oncol 28:15s, 2010 (suppl; abst. 1030)

  • R. Duchnowska, B. Szostakiewicz, T. Jankowski, B. Arlukowicz-Czartoryska, P. J. Wysocki, W. Huang, M. P. Bates, J. Weidler, M. Haddad, J. Jassem : Związek pomiędzy ilościową oceną białka HER2 i ryzykiem przerzutów do mózgu u chorych na rozsianego raka piersi otrzymujących leczenie zawierające trastuzumab. Nowotwory J. oncol. 2011:61 (Supl.2): 36-37

  • G Minuti, M Roncalli, A Fabi, L Landi, J Jassem, R Duchnowska, W Biernat, R Sarnelli, M V-Garcia, F Cappuzzo:MET increased gene copy number and trastuzumab efficacy in HER2 positive metastatic breast cancer patients: preliminary results of an international retrospective collaborative study (submitted to congress IMPAKT)

  • R. Audet, R. Duchnowska, K. Adamowicz, J. Zok, W. Rogowski, M. M. Litwiniuk, S. Debska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft, K. Zabkowska, C. Shen, S. Edgerton, K. V. Nielsen, A. D. Thor, J. C. N. Chang, K. Miller, J. Jassem, G. W. Sledge, B. Leyland-Jones: Thymidilate synthase (TS) gene copy number as predictive marker of capecitabine efficacy in breast cancer patients (submitted to annual ASCO meetig 2011)

  • W. Biernat, R. Duchnowska, B. Szostakiewicz, J. Sperindale, M. Haddad, A. Paquet, Y. Lie, J. Weidler, W. Huang, J. Winslow, T. Jankowski, B. Arlukowicz-Czartoryska, P. J. Wyscki, M. Foszczyńska-Kloda, B. Radecka, M. M. Litwiniuk, S. Debska, M. Bates, _J. Jassem_: Quantitative measurements of p95HER2 (p95) and total HER2 (H2T) protein expression in patients with trastuzumab-treated, metastatic breast cancer (MBC): Independent confirmation od clinical cutoffs. J Clin Oncol 2011, 29, 15S

  • . R. Duchnowska, _J. Jassem_, E. Szutowicz, W. Biernat, T. Jankowski, W. Och, R. Staszkiewicz, M. Chudzik, W. Rogowski, N. Flores, S. Woditschka, L. Li, C. Goswami, M. A. Throat, Y. Gokmen-Polar, G. W. Sledge, P. S. Steeg, D. Palmieri, S. S. Badve: J Clin Oncol 2011, 29, 15S

  • R. Audet, R. Duchnowska. K. Adamowicz, J. ZOk, W. Rogowski, M. M. Litwiniuk, S. Debska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft, K. Zabkowska, C. Shen, S. Edgerton, K. V. Nielsen, A. D. Thor, J. C. N. Chang, K. Miller, _J. Jassem_: Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. J Clin Oncol 2011, 29, 15S

  • R. Duchnowska, B. Szostakiewicz, T. Jankowski, B. Arlukowicz-Czartoryska, P. J. Wysocki, W. Huang, M. P. Bates, J. Weidler, M. Haddad, _J. Jassem_: High HER2 protein level is associated with increased risk of brain metastasis (BM) in patients with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy 7^th Central European Oncology Congress, Opatija, Croatia, June 12-15, 2011 Final Program & Abstract Book, 59.

  • M. T. Skrzypski, R. Dziadziuszko, A. Szymanowska, E. Jassem, P. Czapiewski, W. Biernat, R. Pawłowski, W. Rzyman, _J. Jassem_: Three-microRNA expression profile is related to the risk of dissemination and prognosis i early stage squamous cell lung cancer (SQCLC). Proceedings of the 14^th World Conference on Lung Cancer, Book 2 J Thor Oncol 2011, 6, Suppl. 2, S1075-S1076

  • R. Dziadziuszko, M. W. Wynes, S. Singh, B. G. Reyna Assuncion, J. Ranger-Moore, K. Konopa, W. Rzyman, B. Szostakiewicz, _J. Jassem_, F. R. Hirsch: Correlation between met gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small-cell lung cancer Proceedings of the 14^th World Conference on Lung Cancer, Book 2 J Thor Oncol 2011, 6, Suppl. 2, S1103

  • J. Jassem: Is It Time to Review the Common Toxicity Criteria in the Era of New Targeted Drugs? 2011 European Multidisciplinary Cancer Congress Ecco16/ESMO36/ESTRO30 Stockholm, 23-27 September 2011 Eur J Cancer 2011; 47: Suppl. 1, s86

  • R. Duchnowska, B. Szostakiewicz, R. Dziadziuszko, T. Mandat, W. Olszewski, B. Jarosz, B. Czartoryska-Arłukowicz, B. Radecka, W. Biernat, J. Jassem: Receptor Conversion in Breast Cancer Brain Metastases (BM) 2011 European Multidisciplinary Cancer Congress Ecco16/ESMO36/ESTRO30 Stockholm, 23-27 September 2011 Eur J Cancer 2011; 47: Suppl. 1, s355

  • R. Duchnowska, W. Biernat, B. Szostakiewicz, J. Sperinde, F. Piette, M. Haddad, A. Paquet, Y. Lie, B. Czartoryska-Arlukowicz, P. Wysocki, T. Jankowski, B. Radecka, M. Foszczynska-Kloda, M. Litwiniuk, S. Debksa, J. Weidler, W. Huang, M. Buyse, M. Bates, J. Jassem: Correlation between Quantitative HER2 Protein Expression and Risk of Brain Metastases in HER-2 Positive Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy Cancer Res 2011; 71: 291s, P2-12-05

  • R.M. Audet, S. Changyu, R. Duchnowska, K. Adamowicz, J. Zok, W. Rogowski, M. Litwiniuk, S. Dębska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft, K. Zabkowska, J. Jassem, S. Edgerton, K. Vang Nielsen, A. Thor, J. Chang, K. Miller, G.W. Sledge, B. Leyland-Jones: Gene Copy Number and Expression of TYMP and TYMS Are Predictive of Outcome in Breast Cancer Patients Treated with Capecitabine Cancer Res 2011; 71: 514s-515s, P5-01-06

  • G. Minuti, R. Duchnowska, J. Jassem, M. Roncalli, T. O?Brien, A. Fabi, L. Landi, R. Di Marsico, W. Biernat, B. Czartoryska-Arlukowicz, T. Jankowski, D. Zuziak, J. Zok, B. Szostakiewicz, M. Foszczycnak-Kloda, A. Tempinska_Szalach, E. Rossi, M. Varella-Garcia, F. Capuzzo: /MET /and Hepatocyte Growth Factor (HGF) Increased Gene Copy Number Is Associated to Trastuzumab Failure in HER2 Positive Metastatic Breast Cancer (MBC). Cancer Res 2011; 71: 552s, P5-13-07

  • R. Duchnowska, B. Szostakiewicz, T. Jankowski, B. Arlukowicz-Czartoryska, P. J. Wysocki, W. Huang, M. P. Bates, J. Weidler, M. Haddad, J. Jassem. Związek pomiędzy ilościową oceną białka HER2 i ryzykiem przerzutów do mózgu u chorych na rozsianego raka piersi otrzymujących leczenie zawierające trastuzumab. Nowotwory J Oncol. 2011:61 (Supl.2): 36-37 .

  • GMinuti, M Roncalli, A Fabi, L Landi, J Jassem, R Duchnowska, W Biernat, R Sarnelli, M V-Garcia, F Cappuzzo. MET increased gene copy number and trastuzumab efficacy in HER2 positive metastatic breast cancer patients: preliminary results of an international retrospective collaborative study. Ann Oncol 2011; 22 (supl 2): ii29.

  • J. Jassem, R. Duchnowska, W. Biernat, L. M. Evans, D. P. Fitzgerald, S. Woditschka, B. Szostakiewicz, T. Mandat, B. Jarosz, T. Trojanowski, F. Szubstarski, B. Arlukowicz-Czartoryska, R. Staszkiewicz, B. Szostak, W. Olszewski, P. S. Steeg, L. Li, G. W. Sledge, D. Palmieri, S. S. Badve. Molecular analysis of matched primary tumors and brain metastases of breast cancer reveals the neuronal cell adhesion molecule L1CAM as a therapeutic target. J Clin Oncol 2011: 29 (supl; abstr e21138).

  • R. Duchnowska, J. Jassem, E. Szutowicz, W. Biernat, T. Jankowski, W. Och, R. Staszkiewicz, M. Chudzik, W. Rogowski, N. Flores, S. Woditschka, L. Li, C. Goswami, M. A. Thorat, Y. Gokmen-Polar, G. W. Sledge, P. S. Steeg, D. Palmieri, S. S. Badve. RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer. JClin Oncol 29: 2011 (suppl; abstr 634).

  • W. Biernat, R. Duchnowska, B. Szostakiewicz, J. Sperindale, M. Haddad,A. Paquet, Y. Lie, J. Weidler, W. Huang, J. Winslow, T. Jankowski, B.Arlukowicz-Czartoryska, P. J. Wyscki, M. Foszczyńska-Kloda, B. Radecka,M. M. Litwiniuk, S. Debska, M. Bates, _J. Jassem. Quantitative measurements of p95HER2 (p95) and total HER2 (H2T) proteinexpression in patients with trastuzumab-treated, metastatic breast cancer (MBC): Independent confirmation of clinical cutoffs. J Clin Oncol 2011, 29, 15S.

  • R. Audet, R. Duchnowska. K. Adamowicz, J. Żok, W. Rogowski, M. M.Litwiniuk, S. Debska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft,K. Zabkowska, C. Shen, S. Edgerton, K. V. Nielsen, A. D. Thor, J. C. N. Chang, K. Miller, J. Jassem. Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. JClin Oncol 2011, 29, 15S

  • R. Duchnowska, B. Szostakiewicz, T. Jankowski, B.Arlukowicz-Czartoryska, P. J. Wysocki, W. Huang, M. P. Bates, J.Weidler, M. Haddad, J. Jassem . High HER2 protein level is associated with increased risk of brain metastasis (BM) in patients with metastatic breast cancer (MBC) treatedwith trastuzumab-containing therapy . 7th Central European Oncology Congress, Opatija, Croatia, June 12-15, 2011. Final Program & Abstract Book, 59 .

  • R. Duchnowska, B. Szostakiewicz, R. Dziadziuszko, T. Mandat, W.Olszewski, B. Jarosz, B. Czartoryska-Arłukowicz, B. Radecka, W. Biernat, J. Jassem. Receptor conversion in breast cancer brain metastases (BM). Eur J Cancer 2011; 47: Suppl. 1, s355.

  • R. Duchnowska, W. Biernat, B. Szostakiewicz, J. Sperinde, F. Piette, M.Haddad, A. Paquet, Y. Lie, B. Czartoryska-Arlukowicz, P. Wysocki, T.Jankowski, B. Radecka, M. Foszczynska-Kloda, M. Litwiniuk, S. Debksa, J.Weidler, W. Huang, M. Buyse, M. Bates, J. Jassem. Correlation between Quantitative HER2 protein expression and risk of brain metastases in HER-2 positive advanced breast cancer patients receiving trastuzumab-containing therapy. Cancer Res 2011; 71: 291s, P2-12-05.

  • R. M. Audet, S. Changyu, R. Duchnowska, K. Adamowicz, J. Zok, W.Rogowski, M. Litwiniuk, S. Dębska, M. Jaworska, M. Foszczynska-Kloda, M.Kulma-Kreft, K. Zabkowska, J. Jassem, S. Edgerton, K. Vang Nielsen, A.Thor, J. Chang, K. Miller, G.W. Sledge, B. Leyland-Jones. Gene copy number and expression of TYMP and TYMS are predictive of outcome in breast cancer patients treated with capecitabine. Cancer Res 2011; 71: 514s-515s, P5-01-06

  • G. Minuti, R. Duchnowska, J. Jassem, M. Roncalli, T. O?Brien, A. Fabi,L. Landi, R. Di Marsico, W. Biernat, B. Czartoryska-Arlukowicz, T.Jankowski, D. Zuziak, J. Zok, B. Szostakiewicz, M. Foszczycnak-Kloda, A.Tempinska_Szalach, E. Rossi, M. Varella-Garcia, F. Capuzzo. MET and hepatocyte growth factor (HGF) increased gene copy number is associated to trastuzumab failure in HER2 positive metastatic breast cancer (MBC). Cancer Res 2011; 71: 552s, P5-13-07

  • <--20120924-->
  • R. Duchnowska, J. Jassem, C. Pankaj Goswami, Y. Gokmen-Polar, L. Li, M.A. Thorat, N. Flores, E. Hua, S. Woditschka, D. Palmieri, S. M. Steinberg, W. Biernat, K. Sosinska-Mielcarek, B. Szostakiewicz, B. Czartoryska-Arlukowicz, B. Radecka, Z. Tomasevic, G. W. Sledge, P. S. Steeg, S. S. Badve, Polish Brain Metastasis Consortium.13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. /J Clin Oncol/ 2012; 30 (supl; abstr 505).

  • W. Biernat, R. Duchnowska, T. Trojanowski, T. Mandat, A. Kowalczyk, B. Czartoryska-Arlukowicz, B. Radecka, B. Jarosz, R. Staszkiewicz, E. Kalinka-Warzocha, M. Chudzik, J. Sperinde, M. Haddad, A. Paquet, Y. Lie, J. W. Winslow, J. M. Weidler, W. Huang, C. J. Petropoulos, J. Jassem, Polish Brain Metastasis Consortium. Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases. /J Clin Oncol/2012;30 (supl; abstr. 603).

  • S. Woditschka, D. Palmieri, R. Duchnowska, J. Jassem, S. Badve, G.W. Sledge, Jr., P.S. Steeg. Overexpression of RAD51 promotes brain metastases from breast cancer Cancer Res /2012;72 (suppl 1, abstr. 5306).

CONTACT

Home
 
Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street
80-211 Gdańsk, Poland 
 
email
Phone: +48 58 349 2282
Fax: +48 58 349 22 44
E-mail: Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie obsługi JavaScript.